Clinical Trials Logo

CAR clinical trials

View clinical trials related to CAR.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05691153 Recruiting - B Cell Lymphoma Clinical Trials

ThisCART19A for B-NHL Relapsed After Auto-CAR T

Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, single-center, dose selection study to evaluate the efficacy, safety, and pharmacokinetics of ThisCART19A (allogeneic CAR-T targeting CD19) in patients with Auto-CAR T relapsed B-cell non-Hodgkin's lymphoma.

NCT ID: NCT05679687 Recruiting - Clinical trials for Refractory Acute Lymphoblastic Leukemia

ThisCART19A Bridging to alloHSCT for R/R B-ALL

Start date: December 1, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) bridging to HSCT in patients with refractory or relapsed B cell acute lymphoblastic leukemia (r/r B-ALL).

NCT ID: NCT05648019 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Start date: March 15, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to describe feasibility of delivering point-of-care manufactured CD19-directed CAR T-cell therapy to patients with relapsed/ refractory B-lineage leukaemia/ lymphoma.

NCT ID: NCT05429905 Recruiting - Clinical trials for Lymphoblastic Leukemia

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

Start date: July 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to deliver dual-targeting CAR-T cell therapy (CART 2219.1) as a salvage treatment to patients with relapsed/refractory B-lineage leukaemia in place of stem cell transplant or irradiation.

NCT ID: NCT05043571 Recruiting - Clinical trials for Lymphoblastic Leukemia

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

Start date: September 8, 2021
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).

NCT ID: NCT05038696 Recruiting - Clinical trials for Lymphoblastic Leukemia

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

ALaCART
Start date: April 28, 2021
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).

NCT ID: NCT05017883 Recruiting - Clinical trials for Acute Myeloid Leukemia

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This is a clinical study of ytaa05 cell injection in the treatment of patients with recurrent / refractory acute myeloid leukemia.The purpose is to evaluate the safety and preliminary efficacy of FLT3 car-t cells in patients with recurrent / refractory FLT3 positive acute myeloid leukemia.#TAA05 cell injection is a T cell targeting FLT3 chimeric antigen receptor#

NCT ID: NCT04702841 Recruiting - Malignant Tumors Clinical Trials

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

Start date: June 3, 2020
Phase: Early Phase 1
Study type: Interventional

This is a study on the clinical application of chimeric antigen receptor modified γδ T cells (CAR - γδ T cells) in relapsed and refractory CD7 Positive T cell-derived malignant tumors.The main purpose of this study was to evaluate the efficacy of car - γ δ T cell infusion in patients with relapsed and refractory CD7 Positive T cell-derived malignancies.

NCT ID: NCT04700319 Recruiting - CAR Clinical Trials

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

Start date: April 19, 2019
Phase: Early Phase 1
Study type: Interventional

This is a clinical study of CD19 / CD20 CAR-T cell infusion in the treatment of relapsed or refractory hematological malignancies in CD19 / CD20 positive B cell lines. The aim of this study was to evaluate the efficacy and safety of autologous chimeric antigen receptor T cell infusion targeting CD19/CD20 in the treatment of relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies.

NCT ID: NCT04692948 Recruiting - Clinical trials for Acute Myeloid Leukemia

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

This is a clinical study of TAA6 cell injection in the treatment of patients with relapsed / refractory Acute Myeloid Leukemia . The purpose is to evaluate the safety and effectiveness of CD276 targeted autologous chimeric antigen receptor T cells infusion in patients with relapsed / refractory CD276 positive Acute Myeloid Leukemia.(TAA6 cell injection is a T cell targeting CD276 chimeric antigen receptor)